Abstract 3226
Background
BRAF V600 mutation was considered as a negative prognostic factor in metastatic (stage IV) melanoma patients (pts). Nowadays, two effective systemic treatment modalities - targeted therapy with BRAF+MEK inhibitors and immunotherapy are available for this group of pts contrary to BRAF-wild-type patients where only immunotherapy is used. It is unclear what is the outcome of therapy and treatment sequence in advanced melanoma patients with BRAF-positive and negative patients in the routine practice.
Methods
In this retrospective one-center study, we included 276 (134, 48.6% BRAF V600 mutated) consecutive pts with unresectable/metastatic stage III/IV melanoma treated between 01/2016 and 02/2018. Kaplan-Meier survival probability estimation and Cox’s proportional hazards model were used for analysis.
Results
The first line treatment comprised of anti-PD1 antibodies (in 167 cases, i.e. all BRAF-negative and 25 BRAF-mutant pts) and BRAF/MEK inhibitors (in 109 cases BRAF+ pts). The 1-year overall survival (OS) rates were 61.6% (95% confidence interval, CI: 53.4-71.1) in BRAF-negative pts, 61.1% (95%CI: 51.8-72.1) and 77.3% (95%CI: 61.6-97.1) in BRAF-mutated pts who started BRAF/MEK inhibitors or anty-PD1 antibodies as the first line treatment, respectively. In the multivariable model adjusted for age, sex and LDH level BRAF-mutated pts who received anti-PD1 as 1st line treatment had slightly worse first line progression-free survival (HR: 1.91, 95%CI: 1.00-3.63, p = 0.05), but there were no differences in the multivariable model for OS (HR: 0.67, 95%CI: 0.28-1.58, p = 0.35).
Conclusions
The short-term outcomes of advanced melanoma patients treated with modern systemic therapies are similar independently of BRAF V600 mutation status. Numerically, the best survival rates were reached in BRAF-positive pts who received anti-PD1 antibodies as the 1st line treatment, but this effect needs to be confirmed in a larger population study.
Clinical trial identification
Legal entity responsible for the study
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland.
Funding
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland.
Editorial Acknowledgement
Disclosure
A.M. Czarnecka: Honoraria, Speakers’ bureau, Travel expenses reimbursement: Bristol-Myers Squibb, Roche, Novartis, Merck, Pfizer, GlaxoSmithKline. P. Teterycz: Honoraria, Travel expenses reimbursement: Roche, Eli Lilly, Bayer, Novartis. I. Lugowska, P. Rogala, T. Switaj: Honoraria, Speakers' bureau, Travel expenses reimbursement: Bristol-Myers Squibb, Roche, Novartis, Merck, Pfizer, GlaxoSmithKline. P.L. Rutkowski: Honoraria: Bristol-Myers Squibb, Roche, Novartis, Merck, Sharp & Dohme, GlaxoSmithKline; Paid consulting role with Bristol-Myers Squibb, Roche, Merck, Sharp & Dohme, Blueprint Medicines, Amgen; Speakers’ bureau: Novartis, Pfizer, Merck, Sharp & Dohme; Institutional research funding: Bristol-Myers Squibb, Novartis; Travel expenses reimbursement: Novartis,Orphan Drugs.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract